Patrick E Sewell, Founder and Chief Science Officer at Triple Helix Science, highlights the powerful reality that preventative medicine is revealing; but first we must remove the brakes of entrenched healthcare systems and their stifling economics.
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Alex Gauthier at Novartis reviews practical toxicological strategies for managing late-stage nitrosamine drug substance-related impurities (NDSRIs) while maintaining patient safety and development timelines.
Mike King at IQVIA reveals why digital quality documentation is deemed a key enabler in advanced therapy sectors, increasingly influencing how sponsors select manufacturers.
The UK-EU agreement aims to strengthen health security, scientific collaboration and supply-chain resilience, with potential opportunities for pharmaceutical companies.
A weekly roundup of the latest regulatory updates affecting pharmaceutical development, manufacturing and commercialisation, from new guidance and quality standards to GMP requirements, legislative changes and significant medicine approvals.
The FDA has accepted a second investigational new drug (IND) application under Evotec and Bristol Myers Squibb’s strategic protein degradation partnership, with the candidate expected to enter Phase I trials in 2027.
Calla Lily Clinical Care has secured a £700k Innovate UK grant to adapt its intravaginal drug delivery platform for live biotherapeutics and probiotics targeting vaginal microbiome health.
Explore the implementation of PUPSIT and the infrastructure, processes and expertise needed to support sterile filtration compliance under EU GMP Annex 1.
In this whitepaper, explore how human pharmacokinetic data can guide formulation decisions, minimise development risk and help teams select the simplest viable approach for poorly soluble molecules.
Patrick E Sewell, Founder and Chief Science Officer at Triple Helix Science, highlights the powerful reality that preventative medicine is revealing; but first we must remove the brakes of entrenched healthcare systems and their stifling economics.
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.